UBC Acquires Evidinno Outcomes Research
United BioSource LLC (UBC) has made a significant move to enhance its offerings in the field of healthcare research by acquiring Evidinno Outcomes Research Inc. This strategic acquisition is designed to strengthen UBC's position as a leader in evidence generation, particularly in health economics and outcomes research (HEOR), medical affairs, and market access.
Enhancing Real-World Evidence Capabilities
The acquisition underscores UBC’s commitment to advancing its real-world evidence (RWE) capabilities. Evidinno is renowned for its expertise in epidemiology and evidence synthesis, providing the knowledge and tools needed to conduct advanced statistical and economic analysis. By bringing Evidinno into the fold, UBC aims to leverage this expertise to meet the growing demand for high-quality RWE in the healthcare sector.
The Importance of Real-World Evidence
Real-world evidence has become increasingly critical in healthcare decision-making. It provides insights drawn from real-life data, allowing for a better understanding of treatment effectiveness and patient outcomes outside of controlled clinical environments. With Evidinno’s specialized knowledge, UBC is poised to enhance its research capabilities and deliver valuable insights that drive better health outcomes.
Strengthening Market Access Strategies
Market access strategies are crucial for ensuring that new treatments and therapies are available to patients. UBC’s acquisition of Evidinno enables the company to refine its market access strategies by utilizing advanced outcomes research that aligns with payer needs and aligns with value-based care initiatives. This positions UBC to improve patient access to innovative therapies while supporting healthcare providers in delivering the best care possible.
About United BioSource LLC
United BioSource LLC is a leading provider of innovative evidence generation, with a strong focus on enhancing patient outcomes through a variety of research methodologies. As part of UBC’s vision to create impactful healthcare solutions, this acquisition represents a pivotal step in expanding its expertise across multiple domains within the healthcare sphere.
Frequently Asked Questions
What does the acquisition of Evidinno mean for UBC?
The acquisition strengthens UBC's capabilities in evidence generation, health economics, and market access.
How will UBC benefit from Evidinno's expertise?
Evidinno's expertise in real-world evidence and advanced research methods will enhance UBC’s offerings in healthcare research.
What is real-world evidence (RWE)?
RWE refers to data collected outside of controlled clinical trials, offering insights into treatment effectiveness and patient outcomes.
Why is market access important in healthcare?
Market access ensures that patients can obtain necessary treatments, which is crucial for the success of new therapies.
What is UBC's mission?
UBC aims to enhance patient outcomes through innovative evidence generation and comprehensive research methodologies.
